Proton pump inhibitors market

Proton Pump Inhibitors Market, by Type (Omeprazole, Pantaprazole, Rabeprazole, Dexlansoprazole, lansoprazole, and Others), by Disease Indication (Ulcers, Gastroesophageal Reflux Disease, and Others), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Others), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2020 - 2027

Request Free Sample

Oct 2020
CMI4225
175 Pages
Excel & Pdf
Pharmaceutical

Summary

Proton pump inhibitors are drugs mainly used for prolong and profound reduction of stomach acid levels in individuals suffering from gastroesophageal reflux disease, hyperacidity and ulcers. Proton pump inhibitors (PPIs) have a unique mechanism of action as they are given in an inactive form which are lipophilic in nature and readily cross cell membranes into intracellular compartments like the parietal cell canaliculus with acidic environments, then the inactive drug is protonated and rearranged into its active form in acidic environments and irreversibly blocks the gastric proton pump of the gastric parietal cells.

The global proton pump inhibitors market is estimated to be valued at US$ 2.9 billion in 2020 and is expected to exhibit a CAGR of 4.30% during the forecast period (2020-2027).

Figure 1. Global Proton Pump Inhibitors Market, by Market value (US$ Bn), by 2016-2027

The increasing prevalence of obesity in adults and adolescents is leading to various conditions related to gastroesophageal reflux disease such as Barret's esophagus (BE), esophageal erosions and esophageal adenocarcinoma. The US National Library of Medicine report published in 2017 stated that individuals with higher body mass index (BMI) have a higher risk of gastrointestinal diseases such as gastroesophageal reflux disease and can lead to esophageal erosions.

Moreover, increasing prevalence of gastrointestinal diseases such as duodenal ulcers, barrets esophagus, and non-erosive reflux disease (NERD) are the factors expected to drive the global proton pump inhibitor market growth. According to US National Library of Medicine report published in July 2020, more than 60% of individuals are suffering from non- erosive reflux disease (NERD) and 30% of people are suffering from barrets esophagus in the US.

Proton Pump Inhibitors Market Report Coverage

Report Coverage	Details
Base Year:	2019	Market Size in 2020:	US$ 2.9 Bn
Historical Data for:	2016 to 2019	Forecast Period:	2020 to 2027
Forecast Period 2020 to 2027 CAGR:	4.3%	2027 Value Projection:	US$ 3.5 Bn
Geographies covered:	North America: U.S. and Canada Latin America: Brazil, Argentina, Mexico, and Rest of Latin America Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific Middle East: GCC, Israel, and Rest of the Middle East Africa: South Africa, North Africa, and Central Africa
Segments covered:	By Type: Omeprazole, Pantaprazole, Rabeprazole, Dexlansoprazole, lansoprazole, Others. By Disease Indication: Ulcers, Gastroesophageal Reflux Disease, Others. By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Others.
Companies covered:	AstraZeneca PLC/AB, Bayer AG, Pfizer Inc., Cadila Pharmaceuticals Limited, Eisai Pharmaceuticals India Pvt. Ltd, Santarus, Inc., Wyeth, LLC, Janssen Pharmaceutica, Takeda Pharmaceutical Company Limited, Sanofi S.A, Aurobindo Pharma, Perrigo Company plc, Dr. Reddy's Laboratories, Aralez Pharmaceuticals Inc., RedHill Biopharma Ltd (ADR) and Cipla Limited
Growth Drivers:	The increasing prevalence of gastroesophageal reflux disease and ulcers such as peptic ulcers, duodenal ulcers The increasing presence of local/generic drug manufacturers Strong product pipeline, approval of new proton pump inhibitor drugs for treatment of gastroesophageal reflux disease GERD and ulcers
Restraints & Challenges:	Proton pump inhibitors lead to an increase in risk of Clostridium difficile infection of the colon Long term use of PPI may increase risk of osteoporosis-related fractures of the hip, wrist, or spine.

Global Proton Pump Inhibitors Market – Impact of Coronavirus (COVID-19)

Following the outbreak of COVID-19 in December 2019, the disease has spread to over 100 countries across the globe and the World Health Organization has declared it a public health emergency. According to the World Health Organization’s report, the manifestation of the coronavirus (COVID-19) has resulted in more than 34,804,348 infected individuals worldwide as of 4th October 2020.

COVID-19 can affect tin three main ways; by directly affecting the production and demand; by creating disruptions in distribution channels; and by its financial impact on firms and financial markets. Supply chain and manufacturing activities in India, China, and the U.S. have been disrupted due to nationwide lockdowns. While countries such as Saudi Arabia, UAE, Egypt, and others are facing problems with regards to transportation of drugs from one place to another. Moreover, individuals using proton pump inhibitors medication for longer term duration are more prone towards getting infected by COVID-19 infections. According to the National Library of Medicine Report published in August 2020, use of proton pump inhibitors can increase risk of COVID-19. Moreover, individuals using proton pump inhibitors twice daily are more likely to get infected by COVID-19. These factors are restraining the growth of global proton pump inhibitor market. Therefore, COVID-19 pandemic has also hampered the global proton pump inhibitor market in negative way.

Figure 2. Global Proton Pump Inhibitors Market share (%), by Region, 2020

Among regions, the North America market is expected to witness significant growth owing to an increasing approvals of proton pump inhibitors products. For instance, in 2017, AstraZeneca plc/AB, a biopharmaceutical and pharmaceutical company, received the U.S. Food Drug and Administration’s approved for use of Nexium (esomeprazole magnesium), for treating gastroesophageal reflux disease in children in the age group of 1 to 11 for short term use.

The Europe proton pump inhibitor market is expected to exhibit significant growth during the forecast period owing to increasing focus of key players on obtaining approvals and on launching products. For instance, in April 2018, Perrigo Company plc and its partner, Dexcel Pharma Technologies, Ltd, announced the launch of novel omeprazole orally disintegrating tablet omeprazole OD, omeprazole OD mouth dissolving tablet approved by the U.S. FDA with MelTech melt-in-your-mouth technology, which dissolves the tablet without water in the mouth. Ompeprazole OD is an over-the-counter medication for treating heartburn.

Key Players

Major players operating in the global proton pump inhibitors market are AstraZeneca PLC/AB, Bayer AG, Pfizer Inc., Cadila Pharmaceuticals Limited, Eisai Pharmaceuticals India Pvt. Ltd, Santarus, Inc., Wyeth, LLC, Janssen Pharmaceutica, Takeda Pharmaceutical Company Limited, Sanofi S.A, Aurobindo Pharma, Perrigo Company plc, Dr. Reddy's Laboratories, Aralez Pharmaceuticals Inc., RedHill Biopharma Ltd (ADR) and Cipla Limited.

Table of Content

*Browse 33 market data tables and 32 figures on "Proton Pump Inhibitor Market – global forecast to 2027”.

N/A

- Frequently Asked Questions -

What is the market size and compound annual growth rate (CAGR) of the market during the forecast period (2020-2027)?

The global proton pump inhibitor market size is estimated to be valued at US$ 2.9 billion in 2020 and is expected to exhibit a CAGR of 4.30 % between 2020 and 2027.

What are the major drivers for the global proton pump inhibitor market growth?

The increasing prevalence of gastro-intestinal diseases such as duodenal ulcers, gastroesophageal reflux diseases, rising prevalence of obesity in adults which influences GI diseases, strong product pipeline, approval of new proton pump inhibitor drugs for treatment of gastroesophageal reflux disease GERD and ulcers are driving growth of the global proton pump inhibitors market.

Which is the leading disease indication segment in the global proton pump inhibitors market?

Gastroesophageal reflux disease GERD segment is estimated to hold major market share in 2020, owing to the increasing prevalence of gastroesophageal reflux disease in children and adults.

Which region is estimated to generate the largest market share in 2020 in the global proton pump inhibitors market?

North America is estimated to generate the highest revenue share in 2020 in the global proton pump inhibitors market during the forecast period.

What are the key factors hampering growth of the market?

Long term use of proton pump inhibitors leads to toxic epidermal necrolysis and also leads to reduction in kidney functions, prolonged use also reduces absorption of vitamin B12 (cyanocobalamin) is a key factor hampering growth of the market.

Proton pump inhibitors market

Proton Pump Inhibitors Market Report Coverage

Table of Contents

- Frequently Asked Questions -

What is the market size and compound annual growth rate (CAGR) of the market during the forecast period (2020-2027)?

What are the major drivers for the global proton pump inhibitor market growth?

Which is the leading disease indication segment in the global proton pump inhibitors market?

Which region is estimated to generate the largest market share in 2020 in the global proton pump inhibitors market?

What are the key factors hampering growth of the market?

Which are the major players operating in the market?

Reliability and reputation

Secure Payments By: